T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.
Saved in:
| Title: | T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study. |
|---|---|
| Authors: | Wolf AS; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway. Electronic address: asia-sophia.wolf@fhi.no., Bjørlykke KH; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Ørbo HS; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Bhandari S; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway., Solum G; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway., Kjønstad IF; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway., Jyssum I; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Nygaard UC; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway., Kristoffersen AB; Division of Infection Control, Section for Modelling and Bioinformatics, Norwegian Institute of Public Health, Oslo, Norway., Christensen IE; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Josefsson SE; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway., Lund KP; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B Cell Malignancy, University of Oslo, Oslo, Norway., Chopra A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway., Osen JR; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B Cell Malignancy, University of Oslo, Oslo, Norway., Chaban V; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B Cell Malignancy, University of Oslo, Oslo, Norway., Tveter AT; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway., Sexton J; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Kvien TK; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Jahnsen J; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Haavardsholm EA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Grødeland G; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway., Vaage JT; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway., Provan SA; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Section for Public Health, Inland Norway University of Applied Sciences, Norway., Kared H; Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B Cell Malignancy, University of Oslo, Oslo, Norway., Lund-Johansen F; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway., Munthe LA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B Cell Malignancy, University of Oslo, Oslo, Norway., Syversen SW; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Institute of Health and Society, University of Oslo, Norway., Goll GL; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Institute of Health and Society, University of Oslo, Norway., Jørgensen KK; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway. Electronic address: Kristin.Kaasen.Jorgensen@ahus.no., Mjaaland S; Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway. |
| Source: | EBioMedicine [EBioMedicine] 2024 Oct; Vol. 108, pp. 105317. Date of Electronic Publication: 2024 Sep 10. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
